Study on Tiragolumab with Atezolizumab and Bevacizumab for Previously-Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria

• Must be 18 years or older.
• Must be able to follow the study procedures.
• Have advanced non-squamous NSCLC that cannot be treated with surgery or radiation.
• For some participants, the tumor must show a specific marker (PD-L1) and not have certain genetic changes (EGFR, ALK, ROS1).
• For others, the tumor must have a specific EGFR genetic change.
• The cancer must have worsened during or after previous treatments.
• Must have measurable cancer according to specific criteria.
• Must have a biopsy confirming the type of cancer before starting the study.
• Must be in good general health with a performance status score of 0 to 2.
• Must have adequate blood and organ function based on lab tests.
• Women of childbearing potential must agree to use effective birth control during the study and for 6 months after.
• Men must agree to use effective birth control during the study and for 6 months after, and not donate sperm.

Exclusion Criteria

• Have had previous treatment with anti-TIGIT or certain other antibodies for NSCLC.
• Have untreated or symptomatic cancer spread to the brain.
• Have a history of certain autoimmune diseases that could be worsened by the study treatment.
• Have a history of certain lung diseases or active lung inflammation.
• Have active tuberculosis or certain viral infections.
• Have had major surgery within 4 weeks before starting the study.
• Have had another type of cancer within the last 5 years, with some exceptions.
• Have had a severe infection within 3 weeks before starting the study.
• Have had a stem cell or organ transplant.
• Have uncontrolled high blood pressure or certain heart conditions.
• Have a history of significant bleeding or blood clotting disorders.
• Are pregnant or breastfeeding, or plan to become pregnant during the study or within 6 months after.